跳至主要内容
临床试验/EUCTR2014-004401-32-Outside-EU/EEA
EUCTR2014-004401-32-Outside-EU/EEA进行中(未招募)不适用

A Double-blind, Multicenter, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Adjunctive Treatment With Oral Levetiracetam, in Epilepsy Patients Aged =16 Years, With Generalized Tonic-clonic (GTC) Seizures

CB Japan Co. Ltd.0 个研究点目标入组 361 人开始时间: 2015年3月2日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
361

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • - An epilepsy patient with generalized tonic-clonic seizures that are classifiable according to the ILAE classification of epileptic seizures (Epilepsia, 1981)
  • - A patient on a stable dose of 1 or 2 anti-epileptic drugs for the last 4 weeks (potassium bromide and sodium bromide for the last 12 weeks) prior to and during the combined baseline period
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 27
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 329
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range 5

排除标准

  • - Presence of any sign (clinical or imaging procedures) suggesting a progressive brain lesion/disease, in particular, progressive disorder with epileptic seizures
  • - Diagnosis of Lennox-Gastaut Syndrome
  • - Confirmed focal epilepsy based on clinical signs (seizure types), with consistent electroencephalogram and magnetic resonance imagining features
  • - A history of convulsive or non-convulsive status epilepticus while taking concomitant anti-epileptic drugs for the last 3 months prior to Visit 1

研究者

发起方
CB Japan Co. Ltd.

相似试验

未知
3 期
A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Fingolimod 0.5 mg Administered Orally Once Daily Versus Placebo in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
JPRN-jRCT2080221916Mitsubishi Tanabe Pharma Corporation, Novartis Pharma K.K.156
已完成
不适用
A Clinical Trial of the Efficacy and Safety of Igatan F Capsulein gingivitis patients or mild to moderate chronic periodontitis patientsDiseases of the digestive system
KCT0001366Myungin Pharm100
进行中(未招募)
不适用
A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel Group, Dose Ranging Study to Assess the Efficacy, Safety, and Pharmacokinetics of an Oral Thrombopoietin Receptor Agonist SB-497115-GR Administered at 50, 75, and 100 mg to Cancer Patients receiving Multiple Cycles of ChemotherapyTreatment of chemotherapy induced thrombocytopenia with carboplatin and paclitaxel in advanced solid tumors.MedDRA version: 6.1Level: HLTClassification code 10029105
EUCTR2004-000368-28-ITGLAXO SMITHKLINE164
已完成
3 期
To evaluate the efficacy and safety of Tranexamic Acid Mouthwash to reduce bleeding in subject undergoing tooth extraction.
CTRI/2022/09/045136Morningside Healthcare Ltd714
进行中(未招募)
不适用
A study to evaluate the effect of a single dose of zolmitriptan (Zomig) nasal spray (0.5 mg, 2.5 mg, or 5 mg) as compared to placebo (0 mg) for the treatment of migraine headaches in children/adolescents ages 12 to 17
EUCTR2010-019203-31-PLAstraZeneca AB1,000